Bilateral Paraneoplastic Orbital Myositis Associated With Malignant Melanoma and Multiple Myeloma

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Samantha V. Hunt ◽  
Helen M. Garrott ◽  
Mandy E. Williams ◽  
Rebecca L. Ford
Keyword(s):  
Multiple Myeloma ◽  
Malignant Melanoma ◽  
Orbital Myositis

A Case of Malignant Melanoma with Multiple Myeloma

1993 ◽  
Vol 5 (2) ◽  
pp. 133
Author(s):  
Heung Ryeol Choi ◽  
Yoon Whoa Cho ◽  
Sang Jang Lee ◽  
Byung In Ro ◽  
Seong Hong Kim
Keyword(s):  
Multiple Myeloma ◽  
Malignant Melanoma

scholarly journals A case of malignant melanoma complicated with multiple myeloma

1984 ◽  
Vol 7 (4) ◽  
pp. 247-253
Author(s):  
Taijiro Ishiyama ◽  
Naoki Sugaya ◽  
Tatsuo Miyayama ◽  
Masakuni Sugimoto ◽  
Yoshihisa Wakabayashi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Malignant Melanoma

Proteasome inhibitors as therapeutics

2005 ◽  
Vol 41 ◽  
pp. 205-218
Author(s):  
Constantine S. Mitsiades ◽  
Nicholas Mitsiades ◽  
Teru Hideshima ◽  
Paul G. Richardson ◽  
Kenneth C. Anderson
Keyword(s):  
Multiple Myeloma ◽  
Drug Class ◽  
Proteasome Inhibitors ◽  
Cell Cycle Regulators ◽  
Current State ◽  
Intracellular Mechanism ◽  
Ubiquitin Proteasome ◽  
Proteasome Pathway ◽  
Hodgkin's Lymphomas ◽  
Clinical Research Data

The ubiquitin–proteasome pathway is a principle intracellular mechanism for controlled protein degradation and has recently emerged as an attractive target for anticancer therapies, because of the pleiotropic cell-cycle regulators and modulators of apoptosis that are controlled by proteasome function. In this chapter, we review the current state of the field of proteasome inhibitors and their prototypic member, bortezomib, which was recently approved by the U.S. Food and Drug Administration for the treatment of advanced multiple myeloma. Particular emphasis is placed on the pre-clinical research data that became the basis for eventual clinical applications of proteasome inhibitors, an overview of the clinical development of this exciting drug class in multiple myeloma, and a appraisal of possible uses in other haematological malignancies, such non-Hodgkin's lymphomas.

Malignant melanoma after psoralen and ultraviolet A (PUVA) therapy

1998 ◽  
Vol 138 (6) ◽  
pp. 1100-1101 ◽  
Author(s):  
Wolf ◽  
SchOllnast ◽  
Hofer ◽  
Smolle ◽  
Kerl
Keyword(s):  
Malignant Melanoma ◽  
Puva Therapy ◽  
Ultraviolet A

Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patients

2000 ◽  
Vol 111 (4) ◽  
pp. 1118-1121 ◽  
Author(s):  
A. Bellahcene ◽  
I. Van Riet ◽  
C. de Greef ◽  
N. Antoine ◽  
M. F. Young ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Protein Expression ◽  
Cell Lines ◽  
Myeloma Cell ◽  
Bone Sialoprotein ◽  
Multiple Myeloma Cell ◽  
Human Multiple Myeloma ◽  
Mrna And Protein Expression
Sign in / Sign up

Export Citation Format

Share Document